Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer (Q39359027)

11 September 2017

title

Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer (English)

1 reference

11 September 2017

1 reference

7

Byoung-Gie Kim

1 reference

11 September 2017

Jin Woo Choi

1

1 reference

11 September 2017

Jeong-Won Lee

2

1 reference

11 September 2017

Jun Ki Kim

3

1 reference

11 September 2017

Hye-Kyung Jeon

4

1 reference

11 September 2017

Jung-Joo Choi

5

1 reference

11 September 2017

Dae Gyu Kim

6

1 reference

11 September 2017

Do-Hyun Nam

8

1 reference

11 September 2017

Hong Joong Kim

9

1 reference

11 September 2017

Seok Hyun Yun

10

1 reference

11 September 2017

Sunghoon Kim

11

1 reference

11 September 2017

publication date

24 April 2012

1 reference

Journal of Molecular Cell Biology

11 September 2017

published in

1 reference

11 September 2017

volume

4

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

164-173

1 reference

p53 and NF-κB: different strategies for responding to stress lead to a functional antagonism

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

TNF-alpha in promotion and progression of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

AIMP2 promotes TNFalpha-dependent apoptosis via ubiquitin-mediated degradation of TRAF2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Cancer-associated splicing variant of tumor suppressor AIMP2/p38: pathological implication in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Double-edged swords as cancer therapeutics: simultaneously targeting p53 and NF-kappaB pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

PIDD mediates NF-kappaB activation in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Alternative splicing in the NF-kappaB signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Molecular mechanism of TNF signaling and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Genetic dissection of protein-protein interactions in multi-tRNA synthetase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Targeting TNF for Treatment of Cancer and Autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

Alternative splicing and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJMCB%2FMJS018

21 January 2018

Identifiers

DOI

10.1093/JMCB/MJS018

1 reference

11 September 2017

1 reference